Curing the Incurable:
Groundbreaking Anti-Necrosis Therapies
Ela Pharma is biotechnology company engaged in the development of innovative drugs that address clinical conditions caused by necrosis. The drug development process is based on a new and ground-breaking platform for Anti-Necrosis Technology. The prevention and treatment of necrosis is significant to the therapy of numerous pathological conditions and diseases.
The Company’s technology is based on a novel and unique approach that directly inhibits an intracellular proteolytic enzyme that plays a critical role in the regulation of necrosis pathway.
Necrosis is one of the main mode of cell death, associated with a wide array of diseases which currently has no drug-based cure. Necrosis consists of a cascade of cellular and molecular events that ultimately lead to cell death to major human organs.
Preventing and treating necrosis is significant to the therapy of many pathological and disease conditions. A partial list of necrosis associated diseases includes: Myocardial Infarction, Ischemic diseases, Brain stroke, Traumatic Brain Injury and Neurodegenerative Diseases, Liver failure, Chronic Hepatitis, Pancreatitis and Acute Macular Degeneration,
Tel-Aviv 6936006, Israel